Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Raw Materials (2023 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Raw Materials for 3 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Raw Materials rose 134.88% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 134.88% increase, with the full-year FY2025 number at $4.1 million, up 134.88% from a year prior.
  • Raw Materials was $4.1 million for Q4 2025 at Phathom Pharmaceuticals, up from $1.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $4.1 million in Q4 2025 to a low of $111000.0 in Q2 2023.
  • A 3-year average of $1.3 million and a median of $1.0 million in 2025 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: surged 1717.12% in 2024, then crashed 50.02% in 2025.
  • Phathom Pharmaceuticals' Raw Materials stood at $561000.0 in 2023, then soared by 208.2% to $1.7 million in 2024, then skyrocketed by 134.88% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Raw Materials are $4.1 million (Q4 2025), $1.0 million (Q3 2025), and $991000.0 (Q2 2025).